Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction (GEMyCE 1)
This study is currently recruiting participants.
Verified December 2012 by State University of New York - Upstate Medical University
Sponsor:
State University of New York - Upstate Medical University
Information provided by (Responsible Party):
State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT01749683
First received: December 12, 2012
Last updated: December 13, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to use MCE (myocardial contrast/perfusion echocardiography) to study and compare short/long term change of myocardial perfusion abnormality and cardiac outcome in diabetic patients after nonfatal MI (heart attack), who are treated with different glucose control agents.
| Condition |
|---|
|
Myocardial Infarction |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction |
Resource links provided by NLM:
Further study details as provided by State University of New York - Upstate Medical University:
Primary Outcome Measures:
- Perfusion abnormalities in nondiabetic and diabetic patients [ Time Frame: short term (3 month) and long term (12 month). ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The effect of different glycemic control strategies on the reduction of coronary injury in diabetic and non-diabetic subjects [ Time Frame: short term (3 month) and long term (12 month) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2011 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 71 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Diabetic and nondiabetic patients will be initially recruited and studied after acute nonfatal MI and revascularization with either PCI or CABG
Criteria
Inclusion Criteria:
- Diabetic and nondiabetic patients will be initially recruited and studied after acute nonfatal MI and revascularization with either PCI or CABG
Exclusion Criteria:
- Patients are excluded if they are older than 70 year old, require mechanical ventilation, are receiving intravenous pressors or hemodynamic support, or if the motion of segments associated with infarct-related artery can not be accurately determined.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01749683
Contacts
| Contact: Kan Liu, MD | 315-464-9574 | liuk@upstate.edu |
| Contact: Annie Pennella, MS | 315-464-9574 | pennella@upstate.edu |
Locations
| United States, New York | |
| SUNY Upstate Medical University | Recruiting |
| Syracuse, New York, United States, 13210 | |
| Contact: Annie Pennella, MS 315-464-9574 | |
| Principal Investigator: Kan Liu, MD | |
Sponsors and Collaborators
State University of New York - Upstate Medical University
More Information
No publications provided
| Responsible Party: | State University of New York - Upstate Medical University |
| ClinicalTrials.gov Identifier: | NCT01749683 History of Changes |
| Other Study ID Numbers: | GEMyCE1 |
| Study First Received: | December 12, 2012 |
| Last Updated: | December 13, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Congenital Abnormalities Infarction Myocardial Infarction Ischemia Pathologic Processes |
Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 19, 2013